Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec

11 Jun 2024

Abstract excerpt

BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus-based gene therapy vector expressing the high-activity factor IX (FIX) variant FIX-R338L, is in development for hemophilia B. One-stage clotting (OS) assays and chromogenic substrate (CS) assays are commonly used to measure FIX-R338L variant activity. Data from ongoing trials suggest FIX activity varies between different OS and CS assays. MATERIAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38863155
DOI: 10.1055/s-0044-1787734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene ElaparvovecPMID 38863155Read ↗

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BSemantic proximity Read ↗

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX VariantSemantic proximity Read ↗

Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia BSemantic proximity Read ↗

Adeno-associated virus-based gene therapy for hemophilia–addressing the gapsSemantic proximity Read ↗

Recombinant Factor IX for Clinical and Research UseSemantic proximity Read ↗

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.Semantic proximity Read ↗

Etranacogene dezaparvovec for hemophilia B gene therapySemantic proximity Read ↗

Gene Therapy for Hemophilias: Opportunities and Challenges for the Clinical LaboratorySemantic proximity Read ↗

The History of Factor XIII Deficiency.Semantic proximity Read ↗

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta studySemantic proximity Read ↗

Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia BSemantic proximity Read ↗

Guidelines for laboratory diagnosis of factor XIII deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.